Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Jefferam1on Mar 22, 2018 2:59pm

144 Views

Post# 27763555

Next Binary Event

Any guess to when and what would be the next Binary event?
1. Smaller Regional deal? And what timeframe?
2. Large deal?
3. Next Phase II Clinical Trial (go to market dosage) beginning in Q3 with results Q4?
4. Does ATB-352 timeline move up the Q? Since it's for acute pain and short timeframes can it be expedited?

Something else?
Looking for ideas of what and when.

Bullboard Posts

Debt-free cannabis company set for next stage of growth